Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Google Secures Pentagon AI Deal for Classified Projects 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
BOSTON, April 24, 2017 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, May 1, 2017 at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended March 31, 2017.
The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The passcode for the conference call is 8375689. To access the slides and live webcast or the subsequent archived recording, visit the “Investors & Media” section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company’s website for two weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing, which are focused on hematologic and solid tumor malignancies.
Contact: Amy Trevvett Vice President, Corporate Communications and Investor Relations 617-502-1881 [email protected] David Pitts Argot Partners 212-600-1902 [email protected]
